ELOXX PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.65 per share for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.65.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-03-31 was $6.00, a 500.00% increase year-over-year.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-03-31 was $1.00.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2016-09-30 was $0.00.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $1.05, a 74.26% decline from fiscal 2020.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $4.08, a 4.45% decline from fiscal 2019.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2019 was $4.27, a 1155.88% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.65 S-1 · filed 2026-09-11 | ||||||
| 2026-03-31 | $1.65 S-1/A · filed 2026-06-04 | $0.15 10-Q · filed 2026-05-05 | |||||
| 2025-12-31 | $0.00 S-1 · filed 2026-09-11 | $0.00 10-K · filed 2026-03-17 | |||||
| 2022-12-31 | $0.00 10-K · filed 2023-03-31 | ||||||
| 2021-12-31 | $1.05 10-K · filed 2022-03-30 | ||||||
| 2021-09-30 | $1.05 10-Q · filed 2021-11-08 | ||||||
| 2021-06-30 | $1.59 10-Q · filed 2021-08-16 | ||||||
| 2020-12-31 | $4.08 10-K · filed 2021-03-12 | ||||||
| 2020-09-30 | $4.31 10-Q · filed 2020-11-06 | ||||||
| 2020-06-30 | $6.00 10-Q · filed 2020-08-07 | ||||||
| 2020-03-31 | $6.00 10-Q · filed 2020-05-08 | ||||||
| 2019-12-31 | $4.27 10-K · filed 2020-03-06 | ||||||
| 2019-09-30 | $12.98 10-Q · filed 2019-11-06 | ||||||
| 2019-06-30 | $1.87 10-Q · filed 2019-08-07 | ||||||
| 2019-03-31 | $1.00 10-Q · filed 2019-05-09 | ||||||
| 2018-12-31 | $0.34 10-K · filed 2019-03-14 | ||||||
| 2018-09-30 | $0.10 10-Q · filed 2018-11-08 | ||||||
| 2018-06-30 | $0.13 10-Q · filed 2018-08-10 | ||||||
| 2017-06-30 | $0.00 10-K · filed 2017-10-13 | ||||||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-22 | ||||||
| 2016-12-31 | $0.00 10-Q · filed 2017-02-10 | ||||||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-14 | ||||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-12 | ||||||
| 2015-12-31 | $0.00 10-Q · filed 2016-02-16 | ||||||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-16 | ||||||
| 2015-07-31 | $0.01 10-K · filed 2018-03-16 | ||||||
| 2014-12-31 | $0.00 10-Q · filed 2015-02-17 | ||||||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-14 | ||||||
| 2014-06-30 | $0.00 10-K · filed 2016-10-13 | ||||||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-09 | ||||||
| 2013-12-31 | $0.00 10-Q · filed 2014-02-14 | ||||||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-14 | ||||||
| 2013-06-30 | $0.00 10-Q · filed 2015-11-16 | ||||||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-15 | ||||||
| 2012-12-31 | $0.00 10-Q · filed 2013-02-14 | ||||||
| 2012-06-30 | $0.00 10-K · filed 2014-09-29 | ||||||
| 2011-06-30 | $0.00 10-K · filed 2013-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |